ID
45703
Descripción
Principal Investigator: Scott M. Dehm, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, MN, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001223 Molecularly-targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signaling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumors. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class, and sub-clonal enrichment in tumors within and between patients. Despite this heterogeneity, one common outcome in tumors with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signaling in CRPC.
Link
Palabras clave
Versiones (1)
- 16/5/23 16/5/23 - Chiara Middel
Titular de derechos de autor
Scott M. Dehm, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, MN, USA
Subido en
16 de mayo de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001223 Analysis of AR Gene Rearrangements in Prostate Cancer
Sample ID, analyte type, body site where sample was obtained, histological type, and tumor status of samples obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Subject ID, gender, prostate cancer onset age, presence of metastases, primary tumor, metastasis, or transformed cell line, and Gleason score of participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Sample ID, analyte type, body site where sample was obtained, histological type, and tumor status of samples obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
Similar models
Sample ID, analyte type, body site where sample was obtained, histological type, and tumor status of samples obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Subject ID, gender, prostate cancer onset age, presence of metastases, primary tumor, metastasis, or transformed cell line, and Gleason score of participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
- Sample ID, analyte type, body site where sample was obtained, histological type, and tumor status of samples obtained from participants with prostate cancer and involved in the "Analysis of AR Gene Rearrangements in Prostate Cancer" project.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C0027627 (UMLS CUI [2,1])
C0007601 (UMLS CUI [3,1])